Evidence map›Paper›PMID 41194255›Full record

ArticleBreast cancer research : BCR2025

Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer.

Guojing Xie, Guangjie Zhang, Junhao Cui, Yanchuan Zhang, Qinghua Li, Zhen Tang, Zhen Song, Xin Xie, Yu Fan, Rong Yu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guojing XieCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Guangjie ZhangDepartment of Clinical Laboratory, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China.
Junhao CuiCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yanchuan ZhangCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Qinghua LiCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhen TangCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhen SongCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xin XieCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yu FanCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Rong YuCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jie LanDivision of Head and Neck Tumor Multimodality Treatment, Cancer Center, Institute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. lanjielanjie@foxmail.com.
Yingshuang WangCollege of Medical Technology, Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Sichuan Key Laboratory of Medical Molecular Testing, Chengdu University of Traditional Chinese Medicine, Chengdu, China. wangyingshuang@cdutcm.edu.cn.

Funding

the National Natural Science Foundation of China 82003001the Noncommunicable Chronic Diseases National Science and Technology Major Project No. 2023ZD0502300the Sichuan Major Science and Technology Projects No.25JBGS0058the Sichuan Science and Technology Program 2025ZNSFSC0578, 2025ZNSFSC0601
6 · The paper itself

Abstract

objectivesTriple negative breast cancer (TNBC) is an aggressive subtype with limitations in therapy. Although cyclin dependent kinase inhibitors (CDKi) have been proven in breast cancer, challenges remain in TNBC. Successful inhibition of CDK4/6 relies on intact Rb tumor suppressor (encoded by tumor suppressor gene RB1). However, in addition to gene mutation or deletion, RB1, as an imprinted gene, also has a mechanism of inactivation due to loss of imprinting (LOI). This study aimed to ascertain the imprinting status of RB1 in TNBC.

methodsWe applied bioinformatic analyses to evaluate methylation differences on the RB1 imprinting control region CpG85 among subtypes of breast cancer. Deregulation of RB1 expression by LOI in TNBC cell lines was further tested by RT-qPCR with stimulation by 5-aza-2-deoxycytidine (DAC) treatment. In addition, RB1 CpG85 methylation levels of circulating cell-free DNA (cfDNA) in plasma was assessed by pyrosequencing in 15 enrolled TNBC patients and 6 non-cancer donors. Survival analysis based on TCGA and GEO databases were performed to explored the potential clinical significance.

resultsBioinformatic analysis showed hypomethylation at CpG85 of RB1 in TNBC, which was further confirmed in cell lines. LOI of RB1 affected its transcription. Analysis of cfDNA showed CpG85 was differentially methylated in TNBC patients, with 6/15 patients displaying hypomethylation at cg18481241 and 1/15 at cg03085377 within CpG85. Patients with hypomethylation of these sites correlated with worse overall survival.

conclusionsRB1 exhibits potential LOI in TNBCs, laying the groundwork for more precise subtyping and treatment of TNBC patients.

Indexed as

Genes, Tumor SuppressorGenomic ImprintingRetinoblastoma Binding ProteinsTriple Negative Breast NeoplasmsUbiquitin-Protein LigasesAdultCell Line, TumorComputational BiologyCpG IslandsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasescfDNAImprinting geneRB1 geneTNBC

Identifiers

PMID41194255
PMCPMC12587649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.